{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.5","upperLimit":"75.5","value":"37.5"},{"groupId":"OG001","lowerLimit":"6.7","upperLimit":"65.2","value":"30.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"description":"ORR for MZL=percentage of participants with complete response (CR)/partial response (PR). ORR for WM=CR/PR/very good partial response (VGPR)/minor response (MR). Response assessed per revised Lugano Classification for MZL \\&per IWWM for WM participants. Per Lugano criteria CR=complete disappearance of all evidence of disease \\& disease-related symptoms. PR=regression of measurable disease \\& no new disease sites. Regression=≥50% decrease in the sum of the products of the diameters (SPD) of index lesions, with no increase in size of other lymph nodes/liver/spleen.Per IWWM criteria CR=disappearance of serum monoclonal immunoglobulin M (IgM) protein by immunofixation with a normal serum IgM level. VGPR=reduction of monoclonal IgM protein \\>90% from baseline. PR=reduction of monoclonal IgM protein between 50-90% from baseline with regression of measurable disease. Regression defined in similar manner as Lugano Classification. MR=reduction of monoclonal IgM protein \\>25% but \\<50% from baseline.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with non-follicular iNHL with MZL as the histology type received umbralisib, 800 mg, orally, QD, until disease progression, unacceptable toxicity, or withdrawal from the study whichever occurred first.","id":"OG000","title":"MZL: Umbralisib"},{"description":"Participants with non-follicular iNHL with WM as the histology type received umbralisib, 800 mg, orally, QD, until disease progression, unacceptable toxicity, or withdrawal from the study whichever occurred first.","id":"OG001","title":"WM: Umbralisib"}],"paramType":"NUMBER","populationDescription":"mITT population included all participants who received at least one dose of study treatment and provided at least some post baseline efficacy assessment.","reportingStatus":"POSTED","timeFrame":"Every 3 cycles (1 Cycle = 28 days) from Day 1 Cycle 1 up to approximately 4.2 years","title":"Overall Response Rate (ORR) as Assessed by Revised Response Criteria for Non- Hodgkin's Lymphoma (Lugano Classification) and Consensus-Based 6th International Workshop on Waldenstrom's Macroglobulinemia (IWWM)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}